Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
Status:
Terminated
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy
with TKIs, in terms of median progression free survival (mPFS), in patients affected by
metastatic renal cancer cell.
Patients receiving the sequence Sunitinib- Axitinib, will receive Sorafenib.
Patients receiving the sequence Pazopanib-Sorafenib, will receive Sunitinib.
Sorafenib dosage 400mg orally, twice a day.
Sunitinib dosage 50 mg 4 weeks on followed by 2 weeks a rest.
The therapy will be continued until disease progression or unacceptable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano